hotspot -WSS

hotspot

author：hotspot 2025-10-02 08:58:34 - browse：2557

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： UpToDate has a racism problem: Dr. Stanley Goldfarb

WSS

STAT Virtual Event: JPM Recap, Live!

Canadians with cystic fibrosis outlive Americans by a decade

Fatty liver disease was alleviated by Lilly’s ‘triple

Stories you might have missed in 2023: health, science, medicine

Hubble vs. James Webb telescope images: See the difference

Vertex cell therapy lets patients with type 1 diabetes stop insulin

focus

hotspot

entertainment

Jerome Adams on the need for new antivirals for Covid

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Sports medicine is finally prioritizing gender equality

STAT wants to know your pick for a great summer read or listen

New air purifier tech could be key to improving indoor air quality

A letter from the executive editor: The 2023 STATUS List

BioMarin wins approval for gene therapy to treat hemophilia A

Fauci's latest grilling in Congress: 9 hours, behind closed doors

At least 13 dead in Texas as scorching temps continue

Medicare Advantage overpayments discussion gets experts fired up

entertainment

Life science postdocs should get big pay hike, NIH panel says

A letter from the executive editor: The 2023 STATUS List

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Dexcom's push to bring CGM to type 2 diabetes patients

Does Paxlovid work in people vaccinated against Covid

A letter from the executive editor: The 2023 STATUS List

explore

explore

Wikipedia

hotspot